[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597899":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":36,"locations":42,"responsibleParty":74,"collaborators":30,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":30,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":30,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":30,"overallStatus":45,"whyStopped":30,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"BrightGene Bio-Medical Technology Co., Ltd.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"5 mg BGM0504","EXPERIMENTAL","5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.",[13],"Drug: BGM0504",{"label":15,"type":10,"description":16,"interventionNames":17},"10 mg BGM0504","10 mg BGM0504 administered SC once a week.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"1 mg Semaglutide","ACTIVE_COMPARATOR","1 mg semaglutide administered SC once a week",[23],"Drug: Semaglutide",[25,31,33],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","BGM0504","Administered SC",[9],null,{"type":26,"name":27,"description":28,"armGroupLabels":32,"otherNames":30},[15],{"type":26,"name":34,"description":28,"armGroupLabels":35,"otherNames":30},"Semaglutide",[19],[37],{"name":38,"role":39,"phone":40,"phoneExt":30,"email":41},"Tahapary","CONTACT","+62 821 1447 2567","dicky.tahapary@ui.ac.id",[43,56,64,69],{"facility":44,"status":45,"city":46,"state":47,"zip":30,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":30},"RS Universitas Indonesia","RECRUITING","Depok","West Java","Indonesia","ID",{"type":51,"coordinates":52},"Point",[53,54],106.81861,-6.4,{"lat":54,"lon":53},{"facility":57,"status":45,"city":58,"state":30,"zip":30,"country":48,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":63,"contacts":30},"RSUP Fatmawati","Jakarta",{"type":51,"coordinates":60},[61,62],106.84513,-6.21462,{"lat":62,"lon":61},{"facility":65,"status":45,"city":58,"state":30,"zip":30,"country":48,"countryCode":49,"cosmosGeoPoint":66,"geoPoint":68,"contacts":30},"RSUP Persahabatan",{"type":51,"coordinates":67},[61,62],{"lat":62,"lon":61},{"facility":70,"status":45,"city":58,"state":30,"zip":30,"country":48,"countryCode":49,"cosmosGeoPoint":71,"geoPoint":73,"contacts":30},"RSUPN Dr. Cipto Mangunkusumo",{"type":51,"coordinates":72},[61,62],{"lat":62,"lon":61},{"type":75,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100597899","phase-3-a-study-of-bgm0504-in-participants-with-type-2-diabetes-in-indonesia-100597899",false,"NCT07064486","A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia","A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* ○ Have been diagnosed with type 2 diabetes mellitus (T2DM);\n\n  * Be on stable treatment with unchanged dose of metformin ≥1500 mg\u002Fday or \\\u003C1500 mg\u002Fday but ≥1000 mg\u002Fday (the maximum tolerated dose) for at least 8 weeks prior to screening\n  * Have a BMI ≥23 kilograms per meter squared (kg\u002Fm²) at screening;\n  * Be of stable weight (± 5%) for at least 3 months before screening;\n  * Have HbA1c between ≥7.5% and ≤11.0% at screening\n\nExclusion Criteria:\n\n* ○ Previous diagnosis of type 1 diabetes, special type diabetes;\n\n  * Have suffered the malignancy within the past 5 years (except cured basal cell carcinoma of the skin, cervical carcinoma in situ), or being evaluated for an underlying malignancy;\n  * Have the acute or chronic pancreatitis;\n  * Known to be allergic to 3 or more kinds of foods or medications, or allergic to GLP-1 agonist or metformin, or have a severe allergic disease (asthma, urticaria, eczematous dermatitis, etc.) at screening;\n  * Have a serious mental illness or speech impediment and be unable to fully understand the study;\n  * Suspected or confirmed history of alcohol or drug abuse;\n  * Have had a history of ≥2 severe hypoglycemic episodes in the past 1 year;\n  * Other conditions that may impact the assessment of investigational products, as determined by the Investigator.","ALL","18 Years","75 Years",{"count":87,"type":88},477,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes",[94],"Type 2 Diabetes (T2DM)","2025-10-27",{"date":97,"type":98},"2025-10-28","ACTUAL",{"date":100,"type":98},"2025-07-04",{"date":102,"type":88},"2026-07-31",{"name":5,"class":6},4]